Observational studyAntimicrobial resistance and infection control2020
The epidemiology of carbapenem-non-susceptible Acinetobacter species in Europe: analysis of EARS-Net data from 2013 to 2017.
Observational study in Antimicrobial resistance and infection control, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Antibiotic resistance among Gram-negative bacteria in bloodstream infections in Shiraz, Iran (2012-2023).AMB Express · 2026Article
- Changes in Susceptibility Profiles ofJournal of clinical medicine · 2026Article
- Phenotypic and Genotypic Characterization of Carbapenem-ResistantInternational journal of microbiology · 2026Article
- Development and validation of an interpretable machine learning-based model for predicting carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- Outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections in intensive care units and prognostic effect of different antimicrobial regimens.Annals of intensive care · 2025Article
- Antimicrobial Resistance of Non-Fermenting Gram-Negative Bacilli in a Multidisciplinary Hospital in Romania.Biomedicines · 2025Article
- Prevalence of multidrug resistant gram-negative bacteria and associated factors among gram-negative blood culture isolates at Tikur Anbessa Specialized Hospital: a retrospective study.BMC infectious diseases · 2025Article
- High Prevalence of Virulence andPathogens (Basel, Switzerland) · 2025Article
- Biological sex influences severity and outcomes inMicrobiology spectrum · 2025Article
- Metallo Beta Lactamase Enzymes.Indian journal of microbiology · 2025Review
- Prediction Methods for Antimicrobial Resistance Trends in China.Indian journal of microbiology · 2025Article
- Blue benzoquinone from scorpion venom shows bactericidal activity against drug-resistant strains of the priority pathogen Acinetobacter baumannii.The Journal of antibiotics · 2025Article
- CRAB-RSS: development and validation of a single-center risk stratification model for carbapenem-resistantFrontiers in cellular and infection microbiology · 2025Article
- The intricacies ofFrontiers in microbiology · 2025Review
- The Synergy of Machine Learning and Epidemiology in Addressing Carbapenem Resistance: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2024Review
- Nosocomial transmission ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Risk factors for transmission of carbapenem-resistant Acinetobacter baumannii in outbreak situations: results of a case-control study.BMC infectious diseases · 2024Article
- Risk Factors for Development and Mortality of Bloodstream Infections Caused by Carbapenem-ResistantInfection and drug resistance · 2024Article
- Epidemiological and Clinical Insights intoInternational journal of general medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to limited therapeutic options and their association with high mortality and morbidity, carbapenem-non-susceptible Acinetobacter spp. (CNA) are of significant public health importance. This study aimed to describe current epidemiological trends of CNA proportions in Europe and to identify factors that are associated with carbapenem non-susceptibility of isolates from patients with invasive Acinetobacter spp. infections.
methodsData from routine carbapenem susceptibility testing of 18,412 invasive clinical Acinetobacter spp. isolates from 30 European countries in 2013-2017 were analysed using descriptive statistical analyses and uni- and multivariable regression analyses. These data were obtained from the European Antimicrobial Resistance Surveillance Network (EARS-Net).
resultsThe population-weighted mean proportion of carbapenem-non-susceptible Acinetobacter spp. in Europe is 35.6% (95% confidence interval [CI] 29.7-42.0%). With CNA proportions of 75.5% (95% CI 71.2-79.4%) and 71.5% (95% CI 66.7-75.9%) the burden of CNA is particularly high in Southern and Eastern European regions. In contrast, Northern and Western European regions recorded CNA proportions of 2.8% (95% CI 1.2-6.0%) and 6.3% (95% CI 4.5-8.9%), respectively. Population-weighted mean CNA proportions are especially high in Acinetobacter spp. isolates from intensive care units (54.0% [95% CI 47.6-60.3%]). Male gender, age above 20 years and ICU admission were identified as independent factors associated with an increased likelihood of CNA.
conclusionThe burden of carbapenem-non-susceptible Acinetobacter spp. is particularly high in Southern and Eastern Europe. There is a risk that resistance could spread to other parts of Europe. Therefore, increased efforts in infection control and antibiotic stewardship, particularly in Intensive Care Units, are necessary to combat the spread of CNA in Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.